Nemaura Medical (NASDAQ:NMRD) versus Daxor (NASDAQ:DXR) Head to Head Comparison

Nemaura Medical (NASDAQ:NMRD) and Daxor (NASDAQ:DXR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

Analyst Ratings

This is a summary of current ratings for Nemaura Medical and Daxor, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nemaura Medical	0	0	0	0	0.00
Daxor	0	0	1	0	3.00

Daxor has a consensus target price of $24.75, suggesting a potential upside of 210.54%. Given Daxor’s stronger consensus rating and higher possible upside, analysts plainly believe Daxor is more favorable than Nemaura Medical.

Profitability

This table compares Nemaura Medical and Daxor’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nemaura Medical	N/A	N/A	N/A
Daxor	N/A	N/A	N/A

Valuation and Earnings

This table compares Nemaura Medical and Daxor”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nemaura Medical	$3,017.00	0.00	-$14.14 million	($0.39)	N/A
Daxor	$2.61 million	14.80	N/A	N/A	N/A

Daxor has higher revenue and earnings than Nemaura Medical.

Institutional and Insider Ownership

4.4% of Nemaura Medical shares are owned by institutional investors. Comparatively, 1.3% of Daxor shares are owned by institutional investors. 40.4% of Nemaura Medical shares are owned by company insiders. Comparatively, 59.0% of Daxor shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Risk & Volatility

Nemaura Medical has a beta of 0.27, meaning that its stock price is 73% less volatile than the S&P 500. Comparatively, Daxor has a beta of -0.46, meaning that its stock price is 146% less volatile than the S&P 500.

Summary

Daxor beats Nemaura Medical on 5 of the 7 factors compared between the two stocks.

About Nemaura Medical

Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.

About Daxor

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.